Collegium Pharmaceutical, Inc. Announces Poster Presentation for Oxycodone DETERx® , a Tamper-Resistant, Extended-Release Opioid at 6th Annual Pain Therapeutics Summit
Published: Oct 05, 2012
CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of a scientific poster summarizing the results for Oxycodone DETERx®, its tamper-resistant, extended-release, multi-particulate formulation, demonstrating the effect of crushing techniques on particle size reduction (PSR) and the resulting drug release. Oxycodone DETERx® was evaluated and compared to a commercially available reference product. The poster entitled, “Comparison of the Crush Resistant Properties of Oxycodone DETERx, a Multiparticulate, Extended-Release, Tamper Resistant Formulation Versus a Currently Marketed Oxycodone Extended-Release Product,” was presented at the 6th Annual Pain Therapeutics Summit, held in San Jose, California from October 3-4, 2012.